TBX21 Methylation as a Potential Regulator of Immune Suppression in CMS1 Subtype Colorectal Cancer

Cytotoxic T lymphocyte (CTL) infiltration is associated with survival, recurrence, and therapeutic response in colorectal cancer (CRC). Immune checkpoint inhibitor (ICI) therapy, which requires CTLs for response, does not work for most CRC patients. Therefore, it is critical to improve our understan...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-09, Vol.14 (19), p.4594
Main Authors: Shen, Yuanyuan, Nussbaum, Yulia I, Manjunath, Yariswamy, Hummel, Justin J, Ciorba, Matthew A, Warren, Wesley C, Kaifi, Jussuf T, Papageorgiou, Christos, Cortese, Rene, Shyu, Chi-Ren, Mitchem, Jonathan B
Format: Article
Language:English
Subjects:
Cancer therapies
Classification
Colorectal cancer
Colorectal carcinoma
Cytotoxicity
Datasets
Disease resistance
DNA methylation
Epigenetics
Gene expression
Genetic aspects
Genetic regulation
Genomes
Genomics
Health aspects
Immune checkpoint inhibitors
Immune system
Infiltration
Lymphocytes T
Methylation
Mutation
p53 Protein
Patients
Survival analysis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cytotoxic T lymphocyte (CTL) infiltration is associated with survival, recurrence, and therapeutic response in colorectal cancer (CRC). Immune checkpoint inhibitor (ICI) therapy, which requires CTLs for response, does not work for most CRC patients. Therefore, it is critical to improve our understanding of immune resistance in this disease. We utilized 2391 CRC patients and 7 omics datasets, integrating clinical and genomic data to determine how DNA methylation may impact survival and CTL function in CRC. Using comprehensive molecular subtype (CMS) 1 patients as reference, we found TBX21 to be the only gene with altered expression and methylation that was associated with CTL infiltration. We found that CMS1 patients with high TBX21 expression and low methylation had a significant survival advantage. To confirm the role of Tbx21 in CTL function, we utilized scRNAseq data, demonstrating the association of TBX21 with markers of enhanced CTL function. Further analysis using pathway enrichment found that the genes TBX21, MX1, and SP140 had altered expression and methylation, suggesting that the TP53/P53 pathway may modify TBX21 methylation to upregulate TBX21 expression. Together, this suggests that targeting epigenetic modification more specifically for therapy and patient stratification may provide improved outcomes in CRC.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14194594